$2.51T
Total marketcap
$202.54B
Total volume
BTC 50.10%     ETH 15.71%
Dominance

Genmab A/S GMAB Stock

29.69 USD {{ price }} -0.835003% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
19.45B USD
LOW - HIGH [24H]
29.68 - 30.01 USD
VOLUME [24H]
407.08K USD
{{ volume }}
P/E Ratio
30.92
Earnings per share
0.96 USD

Genmab A/S Price Chart

Genmab A/S GMAB Financial and Trading Overview

Genmab A/S stock price 29.69 USD
Previous Close 38.47 USD
Open 38.45 USD
Bid 0 USD x 800
Ask 0 USD x 900
Day's Range 38.16 - 38.8 USD
52 Week Range 26.94 - 47.5 USD
Volume 678.56K USD
Avg. Volume 385.03K USD
Market Cap 25.61B USD
Beta (5Y Monthly) 0.683524
PE Ratio (TTM) 33.695652
EPS (TTM) 0.96 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 44.3 USD

GMAB Valuation Measures

Enterprise Value 1.38B USD
Trailing P/E 33.695652
Forward P/E 3.1199677
PEG Ratio (5 yr expected) 0.16
Price/Sales (ttm) 1.6706331
Price/Book (mrq) 0.92952186
Enterprise Value/Revenue 0.09
Enterprise Value/EBITDA 0.207

Trading Information

Genmab A/S Stock Price History

Beta (5Y Monthly) 0.683524
52-Week Change 35.77%
S&P500 52-Week Change 20.43%
52 Week High 47.5 USD
52 Week Low 26.94 USD
50-Day Moving Average 40.32 USD
200-Day Moving Average 39.35 USD

GMAB Share Statistics

Avg. Volume (3 month) 385.03K USD
Avg. Daily Volume (10-Days) 324.12K USD
Shares Outstanding 652.56M
Float 644.18M
Short Ratio 9.92
% Held by Insiders 0%
% Held by Institutions 7.05%
Shares Short 3.61M
Short % of Float N/A
Short % of Shares Outstanding 0.54%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 5:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 34.46%
Operating Margin (ttm) 41.21%
Gross Margin 100.00%
EBITDA Margin 43.45%

Management Effectiveness

Return on Assets (ttm) 14.27%
Return on Equity (ttm) 21.17%

Income Statement

Revenue (ttm) 15.33B USD
Revenue Per Share (ttm) 23.46 USD
Quarterly Revenue Growth (yoy) 34.69%
Gross Profit (ttm) 14.6B USD
EBITDA 6.66B USD
Net Income Avi to Common (ttm) 5.28B USD
Diluted EPS (ttm) 1.15
Quarterly Earnings Growth (yoy) -51.39%

Balance Sheet

Total Cash (mrq) 24.54B USD
Total Cash Per Share (mrq) 37.63 USD
Total Debt (mrq) 829M USD
Total Debt/Equity (mrq) 3.05 USD
Current Ratio (mrq) 14.44
Book Value Per Share (mrq) 41.6881

Cash Flow Statement

Operating Cash Flow (ttm) 6.56B USD
Levered Free Cash Flow (ttm) 4.53B USD

Profile of Genmab A/S

Country United States
State N/A
City Copenhagen
Address Kalvebod Brygge 43
ZIP 1560
Phone 45 70 20 27 28
Website https://www.genmab.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1846

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Q&A For Genmab A/S Stock

What is a current GMAB stock price?

Genmab A/S GMAB stock price today per share is 29.69 USD.

How to purchase Genmab A/S stock?

You can buy GMAB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Genmab A/S?

The stock symbol or ticker of Genmab A/S is GMAB.

Which industry does the Genmab A/S company belong to?

The Genmab A/S industry is Biotechnology.

How many shares does Genmab A/S have in circulation?

The max supply of Genmab A/S shares is 655.26M.

What is Genmab A/S Price to Earnings Ratio (PE Ratio)?

Genmab A/S PE Ratio is 30.92708400 now.

What was Genmab A/S earnings per share over the trailing 12 months (TTM)?

Genmab A/S EPS is 0.96 USD over the trailing 12 months.

Which sector does the Genmab A/S company belong to?

The Genmab A/S sector is Healthcare.

Genmab A/S GMAB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD